| 1 |
Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2018
|
| 2 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4834).
|
| 3 |
Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020 Oct;19(10):673-694.
|
| 4 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 5 |
ClinicalTrials.gov (NCT00665223) A Study of Treatment With ACR16 in Patients With Huntington's Disease. U.S. National Institutes of Health.
|
| 6 |
ClinicalTrials.gov (NCT03761849) A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of Intrathecally Administered RO7234292 (RG6042) in Patients With Manifest Huntington's Disease. U.S.National Institutes of Health.
|
| 7 |
Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
|
| 8 |
ClinicalTrials.gov (NCT02352896) Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome. U.S. National Institutes of Health.
|
| 9 |
Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025042)
|
| 10 |
URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8100).
|
| 11 |
ClinicalTrials.gov (NCT03575676) Efficacy and Safety of SOM3355 in Huntington's Disease Chorea. U.S. National Institutes of Health.
|
| 12 |
ClinicalTrials.gov (NCT02507284) Tolerability, Safety, and Activity of SRX246 in Irritable Subjects With Huntington's Disease. U.S. National Institutes of Health.
|
| 13 |
ClinicalTrials.gov (NCT05243017) A Phase Ib/II Study to Explore Safety, Tolerability, and Efficacy Signals of Multiple Ascending Doses of Striatally-Administered rAAV5-miHTT Total Huntingtin Gene (HTT) Lowering Therapy (AMT 130) in Early Manifest Huntington's Disease. U.S.National Institutes of Health.
|
| 14 |
ClinicalTrials.gov (NCT00970229) Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects.. U.S. National Institutes of Health.
|
| 15 |
ClinicalTrials.gov (NCT01031186) First Time in Human Study. U.S. National Institutes of Health.
|
| 16 |
ClinicalTrials.gov (NCT02208934) Study To Assess the Safety and Tolerability of Single Ascending Oral Doses of PBF-999 in Healthy Young Male Volunteers. U.S. National Institutes of Health.
|
| 17 |
Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc (2011).
|
| 18 |
Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
|
| 19 |
Clinical pipeline report, company report or official report of Alnylam Pharmaceuticals, Inc.
|
| 20 |
The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
|
| 21 |
Calmidazolium Chloride and Its Complex with Serum Albumin Prevent Huntingtin Exon1 Aggregation. Mol Pharm. 2018 Aug 6;15(8):3356-3368.
|
| 22 |
Circulating miR-421 Targeting Leucocytic Angiotensin Converting Enzyme 2 Is Elevated in Patients with Chronic Kidney Disease.Nephron. 2019;141(1):61-74. doi: 10.1159/000493805. Epub 2018 Oct 16.
|
| 23 |
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) Enhances Hippocampal Synaptic Plasticity and Improves Memory Performance in Huntington's Disease.Mol Neurobiol. 2018 Nov;55(11):8263-8277. doi: 10.1007/s12035-018-0972-5. Epub 2018 Mar 10.
|
| 24 |
A soluble truncated tau species related to cognitive dysfunction and caspase-2 is elevated in the brain of Huntington's disease patients.Acta Neuropathol Commun. 2019 Jul 30;7(1):111. doi: 10.1186/s40478-019-0764-9.
|
| 25 |
Identification of novel genes in Hirschsprung disease pathway using whole genome expression study.J Pediatr Surg. 2012 Feb;47(2):303-7. doi: 10.1016/j.jpedsurg.2011.11.017.
|
| 26 |
Characterization of somatostatin receptors and associated signaling pathways in pancreas of R6/2 transgenic mice.Biochim Biophys Acta Mol Basis Dis. 2018 Feb;1864(2):359-373. doi: 10.1016/j.bbadis.2017.11.002. Epub 2017 Nov 14.
|
| 27 |
Treatment with the MAO-A inhibitor clorgyline elevates monoamine neurotransmitter levels and improves affective phenotypes in a mouse model of Huntington disease.Exp Neurol. 2016 Apr;278:4-10. doi: 10.1016/j.expneurol.2016.01.019. Epub 2016 Jan 26.
|
| 28 |
Rare homozygosity in amyotrophic lateral sclerosis suggests the contribution of recessive variants to disease genetics.J Neurol Sci. 2019 Jul 15;402:62-68. doi: 10.1016/j.jns.2019.05.006. Epub 2019 May 8.
|
| 29 |
Psychological aspects of pre-symptomatic testing for Machado-Joseph disease and familial amyloid polyneuropathy type I.Clin Genet. 2006 Apr;69(4):297-305. doi: 10.1111/j.1399-0004.2006.00606.x.
|
| 30 |
Targeting ENT1 and adenosine tone for the treatment of Huntington's disease.Hum Mol Genet. 2017 Feb 1;26(3):467-478. doi: 10.1093/hmg/ddw402.
|
| 31 |
Performance of a novel high sensitivity cardiac troponin I assay in asymptomatic hemodialysis patients - evidence for sex-specific differences.Clin Chem Lab Med. 2019 Jul 26;57(8):1261-1270. doi: 10.1515/cclm-2018-1176.
|
| 32 |
Amelioration of Huntington's disease phenotypes by Beta-Lapachone is associated with increases in Sirt1 expression, CREB phosphorylation and PGC-1 deacetylation.PLoS One. 2018 May 9;13(5):e0195968. doi: 10.1371/journal.pone.0195968. eCollection 2018.
|
| 33 |
Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease.Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10483-7. doi: 10.1073/pnas.1832501100. Epub 2003 Aug 20.
|
| 34 |
PKR activation in neurodegenerative disease.J Neuropathol Exp Neurol. 2004 Feb;63(2):97-105. doi: 10.1093/jnen/63.2.97.
|
| 35 |
Trehalose rescues glial cell dysfunction in striatal cultures from HD R6/1 mice at early postnatal development.Mol Cell Neurosci. 2016 Jul;74:128-45. doi: 10.1016/j.mcn.2016.05.002. Epub 2016 May 26.
|
| 36 |
Relationship Between Leptin Level, Inflammation, and Volume Status in Maintenance Hemodialysis Patients.Ther Apher Dial. 2019 Feb;23(1):59-64. doi: 10.1111/1744-9987.12750. Epub 2018 Sep 18.
|
| 37 |
Up-regulation of the isoenzymes MAO-A and MAO-B in the human basal ganglia and pons in Huntington's disease revealed by quantitative enzyme radioautography.Brain Res. 2011 Jan 25;1370:204-14. doi: 10.1016/j.brainres.2010.11.020. Epub 2010 Nov 11.
|
| 38 |
Activation of NPY-Y2 receptors ameliorates disease pathology in the R6/2 mouse and PC12 cell models of Huntington's disease.Exp Neurol. 2018 Apr;302:112-128. doi: 10.1016/j.expneurol.2018.01.001. Epub 2018 Jan 6.
|
| 39 |
Relationship between plasma levels of sclerostin, calcium-phosphate disturbances, established markers of bone turnover, and inflammation in haemodialysis patients.Int Urol Nephrol. 2019 Mar;51(3):519-526. doi: 10.1007/s11255-018-2050-3. Epub 2018 Dec 24.
|
| 40 |
Association Between Toll-Like Receptor 4 (TLR4) and Triggering Receptor Expressed on Myeloid Cells 2 (TREM2) Genetic Variants and Clinical Progression of Huntington's Disease.Mov Disord. 2020 Mar;35(3):401-408. doi: 10.1002/mds.27911. Epub 2019 Nov 14.
|
| 41 |
TRPC5 channel instability induced by depalmitoylation protects striatal neurons against oxidative stress in Huntington's disease.Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118620. doi: 10.1016/j.bbamcr.2019.118620. Epub 2019 Dec 6.
|
| 42 |
HAP1 is an in vivo UBE3A target that augments autophagy in a mouse model of Angelman syndrome.Neurobiol Dis. 2019 Dec;132:104585. doi: 10.1016/j.nbd.2019.104585. Epub 2019 Aug 21.
|
| 43 |
Genomic organization and expression analysis of mouse kynurenine aminotransferase II, a possible factor in the pathophysiology of Huntington's disease.Mamm Genome. 1999 Sep;10(9):845-52. doi: 10.1007/s003359901102.
|
| 44 |
Inhibitors of GABA metabolism: implications for Huntington's disease.Ann Neurol. 1977 Oct;2(4):299-303. doi: 10.1002/ana.410020407.
|
| 45 |
Altered Aconitase 2 Activity in Huntington's Disease Peripheral Blood Cells and Mouse Model Striatum.Int J Mol Sci. 2017 Nov 21;18(11):2480. doi: 10.3390/ijms18112480.
|
| 46 |
Myostatin inhibition prevents skeletal muscle pathophysiology in Huntington's disease mice.Sci Rep. 2017 Oct 27;7(1):14275. doi: 10.1038/s41598-017-14290-3.
|
| 47 |
Increased 5-methylcytosine and decreased 5-hydroxymethylcytosine levels are associated with reduced striatal A2AR levels in Huntington's disease.Neuromolecular Med. 2013 Jun;15(2):295-309. doi: 10.1007/s12017-013-8219-0. Epub 2013 Feb 6.
|
| 48 |
Genetics Modulate Gray Matter Variation Beyond Disease Burden in Prodromal Huntington's Disease.Front Neurol. 2018 Mar 29;9:190. doi: 10.3389/fneur.2018.00190. eCollection 2018.
|
| 49 |
Potential Correlation Between Circulating Fetuin-A and Pentraxin-3 With Biochemical Parameters of Calcification in Hemodialysis Patients.Arch Iran Med. 2017 Dec 1;20(12):752-755.
|
| 50 |
Prevention of cytosolic IAPs degradation: a potential pharmacological target in Huntington's Disease.Pharmacol Res. 2005 Aug;52(2):140-50. doi: 10.1016/j.phrs.2005.01.006.
|
| 51 |
Vascular adhesion protein-1 in hemodialysis and hemodiafiltration patients: effect of single hemodialysis session on its level in regard to type of anticoagulant.Int Urol Nephrol. 2017 May;49(5):875-879. doi: 10.1007/s11255-016-1497-3. Epub 2017 Jan 2.
|
| 52 |
Reducing canonical Wingless/Wnt signaling pathway confers protection against mutant Huntingtin toxicity in Drosophila.Neurobiol Dis. 2012 Aug;47(2):237-47. doi: 10.1016/j.nbd.2012.04.007. Epub 2012 Apr 17.
|
| 53 |
Effect of Apolipoprotein E Genotypes on Huntington's Disease Phenotypes in a Han Chinese Population.Neurosci Bull. 2019 Aug;35(4):756-762. doi: 10.1007/s12264-019-00360-1. Epub 2019 Mar 18.
|
| 54 |
Huntington's disease biomarker progression profile identified by transcriptome sequencing in peripheral blood.Eur J Hum Genet. 2015 Oct;23(10):1349-56. doi: 10.1038/ejhg.2014.281. Epub 2015 Jan 28.
|
| 55 |
Immunohistochemical analysis of huntingtin-associated protein 1 in adult rat spinal cord and its regional relationship with androgen receptor.Neuroscience. 2017 Jan 6;340:201-217. doi: 10.1016/j.neuroscience.2016.10.053. Epub 2016 Oct 29.
|
| 56 |
Blocking acid-sensing ion channel 1 alleviates Huntington's disease pathology via an ubiquitin-proteasome system-dependent mechanism.Hum Mol Genet. 2008 Oct 15;17(20):3223-35. doi: 10.1093/hmg/ddn218. Epub 2008 Jul 24.
|
| 57 |
The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.PLoS One. 2013 Jul 22;8(7):e68951. doi: 10.1371/journal.pone.0068951. Print 2013.
|
| 58 |
Evaluating the SERCA2 and VEGF mRNAs as Potential Molecular Biomarkers of the Onset and Progression in Huntington's Disease.PLoS One. 2015 Apr 27;10(4):e0125259. doi: 10.1371/journal.pone.0125259. eCollection 2015.
|
| 59 |
Effects of simvastatin on neuroprotection and modulation of Bcl-2 and BAX in the rat quinolinic acid model of Huntington's disease.Neurosci Lett. 2008 Dec 19;448(1):166-9. doi: 10.1016/j.neulet.2008.10.023. Epub 2008 Oct 14.
|
| 60 |
Increased complement biosynthesis by microglia and complement activation on neurons in Huntington's disease.Exp Neurol. 1999 Oct;159(2):362-76. doi: 10.1006/exnr.1999.7170.
|
| 61 |
CAG repeat disorder models and human neuropathology: similarities and differences.Acta Neuropathol. 2008 Jan;115(1):71-86. doi: 10.1007/s00401-007-0287-5. Epub 2007 Sep 5.
|
| 62 |
Identification of a novel caspase cleavage site in huntingtin that regulates mutant huntingtin clearance.FASEB J. 2019 Mar;33(3):3190-3197. doi: 10.1096/fj.201701510RRR. Epub 2018 Nov 13.
|
| 63 |
Hyperhomocysteinaemia in treated patients with Huntington's disease homocysteine in HD.Mov Disord. 2004 Feb;19(2):226-8. doi: 10.1002/mds.10629.
|
| 64 |
CD200 is up-regulated in R6/1 transgenic mouse model of Huntington's disease.PLoS One. 2019 Dec 2;14(12):e0224901. doi: 10.1371/journal.pone.0224901. eCollection 2019.
|
| 65 |
Cyclin-Dependent Kinase 5 Dysfunction Contributes to Depressive-like Behaviors in Huntington's Disease by Altering the DARPP-32 Phosphorylation Status in the Nucleus Accumbens.Biol Psychiatry. 2019 Aug 1;86(3):196-207. doi: 10.1016/j.biopsych.2019.03.001. Epub 2019 Mar 13.
|
| 66 |
Smaller low-density lipoprotein size as a possible risk factor for the prevalence of coronary artery diseases in haemodialysis patients: associations of cholesteryl ester transfer protein and the hepatic lipase gene polymorphism with low-density lipoprotein size.Nephrology (Carlton). 2011 Aug;16(6):558-66. doi: 10.1111/j.1440-1797.2011.01454.x.
|
| 67 |
Thecalretinin interneurons of the striatum: comparisons between rodents and primates under normal and pathological conditions.J Neural Transm (Vienna). 2018 Mar;125(3):279-290. doi: 10.1007/s00702-017-1687-x. Epub 2017 Feb 6.
|
| 68 |
Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca(2+) signaling in Huntington's disease.Acta Neuropathol. 2013 May;125(5):727-39. doi: 10.1007/s00401-013-1103-z. Epub 2013 Mar 2.
|
| 69 |
Progressive Cl- channel defects reveal disrupted skeletal muscle maturation in R6/2 Huntington's mice.J Gen Physiol. 2017 Jan;149(1):55-74. doi: 10.1085/jgp.201611603. Epub 2016 Nov 29.
|
| 70 |
Somatostatin and cannabinoid receptors crosstalk in protection of huntingtin knock-in striatal neuronal cells in response to quinolinic acid.Neurochem Int. 2019 Oct;129:104518. doi: 10.1016/j.neuint.2019.104518. Epub 2019 Aug 2.
|
| 71 |
Prospects for cannabinoid therapies in basal ganglia disorders.Br J Pharmacol. 2011 Aug;163(7):1365-78. doi: 10.1111/j.1476-5381.2011.01365.x.
|
| 72 |
Decreased Lin7b expression in layer 5 pyramidal neurons may contribute to impaired corticostriatal connectivity in huntington disease.J Neuropathol Exp Neurol. 2010 Sep;69(9):880-95. doi: 10.1097/NEN.0b013e3181ed7a41.
|
| 73 |
Neuroprotective effects of psychotropic drugs in Huntington's disease.Int J Mol Sci. 2013 Nov 15;14(11):22558-603. doi: 10.3390/ijms141122558.
|
| 74 |
Transducer of regulated CREB-binding proteins (TORCs) transcription and function is impaired in Huntington's disease.Hum Mol Genet. 2012 Aug 1;21(15):3474-88. doi: 10.1093/hmg/dds178. Epub 2012 May 15.
|
| 75 |
High-resolution respirometry of fine-needle muscle biopsies in pre-manifest Huntington's disease expansion mutation carriers shows normal mitochondrial respiratory function.PLoS One. 2017 Apr 13;12(4):e0175248. doi: 10.1371/journal.pone.0175248. eCollection 2017.
|
| 76 |
Two-track virtual screening approach to identify both competitive and allosteric inhibitors of human small C-terminal domain phosphatase 1.J Comput Aided Mol Des. 2017 Aug;31(8):743-753. doi: 10.1007/s10822-017-0037-2. Epub 2017 Jun 26.
|
| 77 |
CYP46A1 gene therapy deciphers the role of brain cholesterol metabolism in Huntington's disease.Brain. 2019 Aug 1;142(8):2432-2450. doi: 10.1093/brain/awz174.
|
| 78 |
The striatal kinase DCLK3 produces neuroprotection against mutant huntingtin.Brain. 2018 May 1;141(5):1434-1454. doi: 10.1093/brain/awy057.
|
| 79 |
RTP801 Is Involved in Mutant Huntingtin-Induced Cell Death.Mol Neurobiol. 2016 Jul;53(5):2857-2868. doi: 10.1007/s12035-015-9166-6. Epub 2015 Apr 16.
|
| 80 |
2,4 DNP improves motor function, preserves medium spiny neuronal identity, and reduces oxidative stress in a mouse model of Huntington's disease.Exp Neurol. 2017 Jul;293:83-90. doi: 10.1016/j.expneurol.2017.03.020. Epub 2017 Mar 28.
|
| 81 |
Complete suppression of Htt fibrilization and disaggregation of Htt fibrils by a trimeric chaperone complex.EMBO J. 2018 Jan 17;37(2):282-299. doi: 10.15252/embj.201797212. Epub 2017 Dec 6.
|
| 82 |
Localized changes to glycogen synthase kinase-3 and collapsin response mediator protein-2 in the Huntington's disease affected brain. Hum Mol Genet. 2014 Aug 1;23(15):4051-63. doi: 10.1093/hmg/ddu119. Epub 2014 Mar 14.
|
| 83 |
Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.J Neurosci. 2008 Sep 24;28(39):9723-31. doi: 10.1523/JNEUROSCI.3044-08.2008.
|
| 84 |
Transcriptional correlates of the pathological phenotype in a Huntington's disease mouse model.Sci Rep. 2019 Dec 10;9(1):18696. doi: 10.1038/s41598-019-55177-9.
|
| 85 |
DRD3 variation associates with early-onset heroin dependence, but not specific personality traits.Prog Neuropsychopharmacol Biol Psychiatry. 2014 Jun 3;51:1-8. doi: 10.1016/j.pnpbp.2013.12.018. Epub 2014 Jan 5.
|
| 86 |
Localization of the D5 dopamine receptor gene to human chromosome 4p15.1-p15.3, centromeric to the Huntington's disease locus.Genomics. 1992 Mar;12(3):510-6. doi: 10.1016/0888-7543(92)90442-u.
|
| 87 |
MAP kinase phosphatase 1 (MKP-1/DUSP1) is neuroprotective in Huntington's disease via additive effects of JNK and p38 inhibition.J Neurosci. 2013 Feb 6;33(6):2313-25. doi: 10.1523/JNEUROSCI.4965-11.2013.
|
| 88 |
Cell cycle activation in striatal neurons from Huntington's disease patients and rats treated with 3-nitropropionic acid.Int J Dev Neurosci. 2008 Nov;26(7):665-71. doi: 10.1016/j.ijdevneu.2008.07.016. Epub 2008 Aug 12.
|
| 89 |
Exploring Genetic Factors Involved in Huntington Disease Age of Onset: E2F2 as a New Potential Modifier Gene.PLoS One. 2015 Jul 6;10(7):e0131573. doi: 10.1371/journal.pone.0131573. eCollection 2015.
|
| 90 |
Correction of Huntington's Disease Phenotype by Genistein-Induced Autophagy in the Cellular Model.Neuromolecular Med. 2018 Mar;20(1):112-123. doi: 10.1007/s12017-018-8482-1. Epub 2018 Feb 12.
|
| 91 |
Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease.Acta Neuropathol. 2017 Nov;134(5):729-748. doi: 10.1007/s00401-017-1732-8. Epub 2017 Jun 7.
|
| 92 |
Dysregulated brain creatine kinase is associated with hearing impairment in mouse models of Huntington disease.J Clin Invest. 2011 Apr;121(4):1519-23. doi: 10.1172/JCI43220. Epub 2011 Mar 14.
|
| 93 |
Cross linking of polyglutamine domains catalyzed by tissue transglutaminase is greatly favored with pathological-length repeats: does transglutaminase activity play a role in (CAG)(n)/Q(n)-expansion diseases?.Neurochem Int. 2002 Jan;40(1):53-67. doi: 10.1016/s0197-0186(01)00058-4.
|
| 94 |
Longitudinal assessment of the Unified Huntington's Disease Rating Scale (UHDRS) and UHDRS-For Advanced Patients (UHDRS-FAP) in patients with late stage Huntington's disease.Eur J Neurol. 2019 May;26(5):780-785. doi: 10.1111/ene.13889. Epub 2019 Jan 27.
|
| 95 |
Differential Impacts of Intravenous Iron Administration and Iron-Containing Phosphate Binders on Serum Intact Fibroblast Growth Factor 23 Levels.Blood Purif. 2019;47 Suppl 2:63-69. doi: 10.1159/000496640. Epub 2019 Apr 3.
|
| 96 |
Expanded polyglutamine impairs normal nuclear distribution of fused in sarcoma and poly (rC)-binding protein 1 in Huntington's disease.Neuropathology. 2019 Oct;39(5):358-367. doi: 10.1111/neup.12600. Epub 2019 Oct 9.
|
| 97 |
A GABBR2 gene variant modifies pathophysiology in Huntington's disease.Neurosci Lett. 2016 May 4;620:8-13. doi: 10.1016/j.neulet.2016.03.038. Epub 2016 Mar 23.
|
| 98 |
Palmitoylation and trafficking of GAD65 are impaired in a cellular model of Huntington's disease.Biochem J. 2012 Feb 15;442(1):39-48. doi: 10.1042/BJ20110679.
|
| 99 |
Mutant huntingtin reduction in astrocytes slows disease progression in the BACHD conditional Huntington's disease mouse model.Hum Mol Genet. 2019 Feb 1;28(3):487-500. doi: 10.1093/hmg/ddy363.
|
| 100 |
Bilateral quinolinic acid-induced lipid peroxidation, decreased striatal monoamine levels and neurobehavioral deficits are ameliorated by GIP receptor agonist D-Ala(2)GIP in rat model of Huntington's disease.Eur J Pharmacol. 2018 Jun 5;828:31-41. doi: 10.1016/j.ejphar.2018.03.034. Epub 2018 Mar 22.
|
| 101 |
Genetic predisposition to advanced glycation end products toxicity is related to prognosis of chronic hemodialysis patients.Kidney Blood Press Res. 2010;33(1):30-6. doi: 10.1159/000285845. Epub 2010 Feb 23.
|
| 102 |
Epigenetic dysregulation of hairy and enhancer of split 4 (HES4) is associated with striatal degeneration in postmortem Huntington brains.Hum Mol Genet. 2015 Mar 1;24(5):1441-56. doi: 10.1093/hmg/ddu561. Epub 2014 Dec 5.
|
| 103 |
Targeting Gpr52 lowers mutant HTT levels and rescues Huntington's disease-associated phenotypes.Brain. 2018 Jun 1;141(6):1782-1798. doi: 10.1093/brain/awy081.
|
| 104 |
Mapping of the human NMDA receptor subunit (NMDAR1) and the proposed NMDA receptor glutamate-binding subunit (NMDARA1) to chromosomes 9q34.3 and chromosome 8, respectively.Genomics. 1993 Jul;17(1):237-9. doi: 10.1006/geno.1993.1311.
|
| 105 |
SorCS2-mediated NR2A trafficking regulates motor deficits in Huntington's disease.JCI Insight. 2017 May 4;2(9):e88995. doi: 10.1172/jci.insight.88995. eCollection 2017 May 4.
|
| 106 |
Rapid homeostatic downregulation of LTP by extrasynaptic GluN2B receptors.J Neurophysiol. 2018 Nov 1;120(5):2351-2357. doi: 10.1152/jn.00421.2018. Epub 2018 Aug 15.
|
| 107 |
Autophagy is increased following either pharmacological or genetic silencing of mGluR5 signaling in Alzheimer's disease mouse models.Mol Brain. 2018 Apr 10;11(1):19. doi: 10.1186/s13041-018-0364-9.
|
| 108 |
Nerve growth factor and striatal glutathione metabolism in a rat model of Huntington's disease.Restor Neurol Neurosci. 2000;17(4):217-221.
|
| 109 |
Basal ganglia lesions in the rat: effects on quinolinic acid metabolism.Brain Res. 1989 Jun 19;490(1):103-9. doi: 10.1016/0006-8993(89)90435-6.
|
| 110 |
Association of Hepcidin With Anemia Parameters in Incident Dialysis Patients: Differences Between Dialysis Modalities.Ther Apher Dial. 2020 Feb;24(1):4-16. doi: 10.1111/1744-9987.12837. Epub 2019 Jun 10.
|
| 111 |
Hypothalamic alterations in Huntington's disease patients: comparison with genetic rodent models.J Neuroendocrinol. 2014 Nov;26(11):761-75. doi: 10.1111/jne.12190.
|
| 112 |
Histone deacetylase-1 (HDAC1) is a molecular switch between neuronal survival and death.J Biol Chem. 2012 Oct 12;287(42):35444-35453. doi: 10.1074/jbc.M112.394544. Epub 2012 Aug 23.
|
| 113 |
A selective inhibitor of histone deacetylase 3 prevents cognitive deficits and suppresses striatal CAG repeat expansions in Huntington's disease mice.Sci Rep. 2017 Jul 20;7(1):6082. doi: 10.1038/s41598-017-05125-2.
|
| 114 |
Hdac4 Interactions in Huntington's Disease Viewed Through the Prism of Multiomics.Mol Cell Proteomics. 2019 Aug 9;18(8 suppl 1):S92-S113. doi: 10.1074/mcp.RA118.001253. Epub 2019 Apr 30.
|
| 115 |
Inhibition of specific HDACs and sirtuins suppresses pathogenesis in a Drosophila model of Huntington's disease.Hum Mol Genet. 2008 Dec 1;17(23):3767-75. doi: 10.1093/hmg/ddn273. Epub 2008 Sep 1.
|
| 116 |
Mitochondrial Dysfunction in Huntington's Disease; Interplay Between HSF1, p53 and PGC-1 Transcription Factors.Front Cell Neurosci. 2019 Mar 19;13:103. doi: 10.3389/fncel.2019.00103. eCollection 2019.
|
| 117 |
Perospirone in treatment of Huntington's disease: a first case report.Prog Neuropsychopharmacol Biol Psychiatry. 2007 Jan 30;31(1):308-10. doi: 10.1016/j.pnpbp.2006.06.021. Epub 2006 Aug 1.
|
| 118 |
Misfolded protein aggregates: mechanisms, structures and potential for disease transmission.Semin Cell Dev Biol. 2011 Jul;22(5):482-7. doi: 10.1016/j.semcdb.2011.04.002. Epub 2011 May 5.
|
| 119 |
Linkage, but not gene order, of homologous loci, including alpha-L-iduronidase (Idua), is conserved in the Huntington disease region of the mouse and human genomes.Mamm Genome. 1992;3(1):23-7. doi: 10.1007/BF00355837.
|
| 120 |
Interferon-3 as a Predictor of Survival in Hemodialysis Patients.Curr Mol Med. 2018;18(4):207-215. doi: 10.2174/1566524018666180926162324.
|
| 121 |
Polymorphisms of T helper cell cytokine-associated genes and survival of hemodialysis patients - a prospective study.BMC Nephrol. 2017 May 19;18(1):165. doi: 10.1186/s12882-017-0582-x.
|
| 122 |
Relationships between interleukin-12B and interleukin-10 gene polymorphisms and hepatitis C in Chinese Han hemodialysis patients.Ren Fail. 2015 Apr;37(3):505-10. doi: 10.3109/0886022X.2015.1006086. Epub 2015 Jan 23.
|
| 123 |
Aberrant calcium signaling by transglutaminase-mediated posttranslational modification of inositol 1,4,5-trisphosphate receptors.Proc Natl Acad Sci U S A. 2014 Sep 23;111(38):E3966-75. doi: 10.1073/pnas.1409730111. Epub 2014 Sep 8.
|
| 124 |
Role of inositol 1,4,5-trisphosphate receptors in pathogenesis of Huntington's disease and spinocerebellar ataxias.Neurochem Res. 2011 Jul;36(7):1186-97. doi: 10.1007/s11064-010-0393-y. Epub 2011 Jan 6.
|
| 125 |
Targeting H3K4 trimethylation in Huntington disease.Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E3027-36. doi: 10.1073/pnas.1311323110. Epub 2013 Jul 19.
|
| 126 |
Development of a Rapid Fluorescence-Based High-Throughput Screening Assay to Identify Novel Kynurenine 3-Monooxygenase Inhibitor Scaffolds.SLAS Discov. 2018 Jul;23(6):554-560. doi: 10.1177/2472555218757180. Epub 2018 Feb 8.
|
| 127 |
Transspinal delivery of drugs by transdermal patch back-of-neck for Alzheimer's disease: a new route of administration.Discov Med. 2019 Jan;27(146):37-43.
|
| 128 |
Rho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.Mol Neurobiol. 2016 May;53(4):2132-40. doi: 10.1007/s12035-015-9147-9. Epub 2015 May 5.
|
| 129 |
Vitamin E suppresses 5-lipoxygenase-mediated oxidative stress in peripheral blood mononuclear cells of hemodialysis patients regardless of administration route. Am J Kidney Dis. 2001 May;37(5):964-9. doi: 10.1016/s0272-6386(05)80012-5.
|
| 130 |
ASK1 and MAP2K6 as modifiers of age at onset in Huntington's disease.J Mol Med (Berl). 2008 Apr;86(4):485-90. doi: 10.1007/s00109-007-0299-6. Epub 2008 Mar 8.
|
| 131 |
Implication of the JNK pathway in a rat model of Huntington's disease.Exp Neurol. 2009 Jan;215(1):191-200. doi: 10.1016/j.expneurol.2008.10.008. Epub 2008 Oct 28.
|
| 132 |
Pathogenic huntingtin inhibits fast axonal transport by activating JNK3 and phosphorylating kinesin.Nat Neurosci. 2009 Jul;12(7):864-71. doi: 10.1038/nn.2346. Epub 2009 Jun 14.
|
| 133 |
Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models.Cell Res. 2017 Dec;27(12):1441-1465. doi: 10.1038/cr.2017.113. Epub 2017 Oct 13.
|
| 134 |
Microstructural changes observed with DKI in a transgenic Huntington rat model: evidence for abnormal neurodevelopment.Neuroimage. 2012 Jan 16;59(2):957-67. doi: 10.1016/j.neuroimage.2011.08.062. Epub 2011 Aug 30.
|
| 135 |
The p. R151C Polymorphism in MC1R Gene Modifies the Age of Onset in Spanish Huntington's Disease Patients.Mol Neurobiol. 2017 Jul;54(5):3906-3910. doi: 10.1007/s12035-016-0305-5. Epub 2016 Dec 6.
|
| 136 |
Significance of serum Myostatin in hemodialysis patients.BMC Nephrol. 2019 Dec 11;20(1):462. doi: 10.1186/s12882-019-1647-9.
|
| 137 |
Astrocyte elevated gene-1 induces autophagy in diabetic cardiomyopathy through upregulation of KLF4.J Cell Biochem. 2019 Jun;120(6):9709-9715. doi: 10.1002/jcb.28249. Epub 2018 Dec 5.
|
| 138 |
The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity.J Neurosci. 2011 Oct 12;31(41):14496-507. doi: 10.1523/JNEUROSCI.3059-11.2011.
|
| 139 |
Risk Factors for Primary Arteriovenous Fistula Dysfunction in Hemodialysis Patients: A Retrospective Survival Analysis in Multiple Medical Centers.Blood Purif. 2019;48(3):276-282. doi: 10.1159/000500045. Epub 2019 May 8.
|
| 140 |
Gintonin, a ginseng-derived ingredient, as a novel therapeutic strategy for Huntington's disease: Activation of the Nrf2 pathway through lysophosphatidic acid receptors.Brain Behav Immun. 2019 Aug;80:146-162. doi: 10.1016/j.bbi.2019.03.001. Epub 2019 Mar 7.
|
| 141 |
TSPO-PET imaging using [18F]PBR06 is a potential translatable biomarker for treatment response in Huntington's disease: preclinical evidence with the p75NTR ligand LM11A-31.Hum Mol Genet. 2018 Aug 15;27(16):2893-2912. doi: 10.1093/hmg/ddy202.
|
| 142 |
Development of 2-thioxoquinazoline-4-one derivatives as dual and selective inhibitors of dynamin-related protein 1 (Drp1) and puromycin-sensitive aminopeptidase (PSA).Chem Pharm Bull (Tokyo). 2014;62(10):979-88. doi: 10.1248/cpb.c14-00333.
|
| 143 |
Association of age at onset in Huntington disease with functional promoter variations in NPY and NPY2R.J Mol Med (Berl). 2014 Feb;92(2):177-84. doi: 10.1007/s00109-013-1092-3.
|
| 144 |
Calcium-sensing receptor gene (CASR) polymorphisms and CASR transcript level concerning dyslipidemia in hemodialysis patients: a cross-sectional study.BMC Nephrol. 2019 Nov 27;20(1):436. doi: 10.1186/s12882-019-1619-0.
|
| 145 |
Do BDNF and NT-4/5 exert synergistic or occlusive effects on corticostriatal transmission in a male mouse model of Huntington's disease?.J Neurosci Res. 2019 Dec;97(12):1665-1677. doi: 10.1002/jnr.24507. Epub 2019 Aug 7.
|
| 146 |
High and Low Levels of an NTRK2-Driven Genetic Profile Affect Motor- and Cognition-Associated Frontal Gray Matter in Prodromal Huntington's Disease.Brain Sci. 2018 Jun 22;8(7):116. doi: 10.3390/brainsci8070116.
|
| 147 |
The impact of single-nucleotide polymorphisms (SNPs) in OGG1 and XPC on the age at onset of Huntington disease.Mutat Res. 2013 Aug 15;755(2):115-9. doi: 10.1016/j.mrgentox.2013.04.020. Epub 2013 Jul 2.
|
| 148 |
CRISPR/Cas9 Editing of the Mutant Huntingtin Allele InVitro and InVivo.Mol Ther. 2017 Jan 4;25(1):12-23. doi: 10.1016/j.ymthe.2016.11.010. Epub 2017 Jan 4.
|
| 149 |
PDE10A mutations help to unwrap the neurobiology of hyperkinetic disorders.Cell Signal. 2019 Aug;60:31-38. doi: 10.1016/j.cellsig.2019.04.001. Epub 2019 Apr 2.
|
| 150 |
Striatal phosphodiesterase mRNA and protein levels are reduced in Huntington's disease transgenic mice prior to the onset of motor symptoms.Neuroscience. 2004;123(4):967-81. doi: 10.1016/j.neuroscience.2003.11.009.
|
| 151 |
Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain.Cell Signal. 2018 Jan;42:281-291. doi: 10.1016/j.cellsig.2017.11.004. Epub 2017 Nov 23.
|
| 152 |
Histone Deacetylase Inhibitors Protect Against Pyruvate Dehydrogenase Dysfunction in Huntington's Disease.J Neurosci. 2017 Mar 8;37(10):2776-2794. doi: 10.1523/JNEUROSCI.2006-14.2016. Epub 2017 Jan 25.
|
| 153 |
The complexity of reproductive decision-making in asymptomatic carriers of the Huntington mutation.Eur J Hum Genet. 2007 Apr;15(4):453-62. doi: 10.1038/sj.ejhg.5201774. Epub 2007 Jan 24.
|
| 154 |
Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases.Prion. 2018 Mar 4;12(2):127-137. doi: 10.1080/19336896.2018.1464367. Epub 2018 May 18.
|
| 155 |
Mutant huntingtin impairs PNKP and ATXN3, disrupting DNA repair and transcription.Elife. 2019 Apr 17;8:e42988. doi: 10.7554/eLife.42988.
|
| 156 |
Characterization of adenine nucleotide metabolism in the cellular model of Huntington's disease.Nucleosides Nucleotides Nucleic Acids. 2018;37(11):630-638. doi: 10.1080/15257770.2018.1481508. Epub 2018 Dec 27.
|
| 157 |
Erucic acid, a nutritional PPAR-ligand may influence Huntington's disease pathogenesis.Metab Brain Dis. 2020 Jan;35(1):1-9. doi: 10.1007/s11011-019-00500-6. Epub 2019 Oct 17.
|
| 158 |
Amelioration of Huntington's disease phenotype in astrocytes derived from iPSC-derived neural progenitor cells of Huntington's disease monkeys.PLoS One. 2019 Mar 21;14(3):e0214156. doi: 10.1371/journal.pone.0214156. eCollection 2019.
|
| 159 |
Putting proteins in their place: palmitoylation in Huntington disease and other neuropsychiatric diseases.Prog Neurobiol. 2012 May;97(2):220-38. doi: 10.1016/j.pneurobio.2011.11.002. Epub 2011 Dec 7.
|
| 160 |
Impact of Weekly Teriparatide on the Bone and Mineral Metabolism in Hemodialysis Patients With Relatively Low Serum Parathyroid Hormone: A Pilot Study.Ther Apher Dial. 2020 Apr;24(2):146-153. doi: 10.1111/1744-9987.12867. Epub 2019 Jul 21.
|
| 161 |
siRNA screen identifies QPCT as a druggable target for Huntington's disease.Nat Chem Biol. 2015 May;11(5):347-354. doi: 10.1038/nchembio.1790. Epub 2015 Apr 6.
|
| 162 |
Infrainguinal bypass surgery outcomes are worse in hemodialysis patients compared with patients with renal transplants.J Vasc Surg. 2019 Mar;69(3):850-856. doi: 10.1016/j.jvs.2018.05.252. Epub 2018 Dec 21.
|
| 163 |
Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region.Am J Hum Genet. 2012 Mar 9;90(3):434-44. doi: 10.1016/j.ajhg.2012.01.005. Epub 2012 Mar 1.
|
| 164 |
MicroRNA-22 (miR-22) overexpression is neuroprotective via general anti-apoptotic effects and may also target specific Huntington's disease-related mechanisms.PLoS One. 2013;8(1):e54222. doi: 10.1371/journal.pone.0054222. Epub 2013 Jan 17.
|
| 165 |
Dysregulation of receptor interacting protein-2 and caspase recruitment domain only protein mediates aberrant caspase-1 activation in Huntington's disease.J Neurosci. 2005 Dec 14;25(50):11645-54. doi: 10.1523/JNEUROSCI.4181-05.2005.
|
| 166 |
Loss of SNAP-25 and rabphilin 3a in sensory-motor cortex in Huntington's disease.J Neurochem. 2007 Oct;103(1):115-23. doi: 10.1111/j.1471-4159.2007.04703.x.
|
| 167 |
Loss of striatal 90-kDa ribosomal S6 kinase (Rsk) is a key factor for motor, synaptic and transcription dysfunction in Huntington's disease.Biochim Biophys Acta. 2016 Jul;1862(7):1255-66. doi: 10.1016/j.bbadis.2016.04.002. Epub 2016 Apr 6.
|
| 168 |
Associations between Soluble Receptor for Advanced Glycation End Products (sRAGE) and S100A12 (EN-RAGE) with Mortality in Long-term Hemodialysis Patients.J Korean Med Sci. 2017 Jan;32(1):54-59. doi: 10.3346/jkms.2017.32.1.54.
|
| 169 |
Stimulation of S1PR5 with A-971432, a selective agonist, preserves blood-brain barrier integrity and exerts therapeutic effect in an animal model of Huntington's disease.Hum Mol Genet. 2018 Jul 15;27(14):2490-2501. doi: 10.1093/hmg/ddy153.
|
| 170 |
A genetic modifier suggests that endurance exercise exacerbates Huntington's disease.Hum Mol Genet. 2018 May 15;27(10):1723-1731. doi: 10.1093/hmg/ddy077.
|
| 171 |
Traditional Chinese medicine on four patients with Huntington's disease.Mov Disord. 2009 Feb 15;24(3):453-5. doi: 10.1002/mds.22447.
|
| 172 |
Identifying therapeutic targets by combining transcriptional data with ordinal clinical measurements.Nat Commun. 2017 Sep 20;8(1):623. doi: 10.1038/s41467-017-00353-6.
|
| 173 |
Pridopidine stabilizes mushroom spines in mouse models of Alzheimer's disease by acting on the sigma-1 receptor.Neurobiol Dis. 2019 Apr;124:489-504. doi: 10.1016/j.nbd.2018.12.022. Epub 2018 Dec 27.
|
| 174 |
SIRT1 is increased in affected brain regions and hypothalamic metabolic pathways are altered in Huntington disease.Neuropathol Appl Neurobiol. 2019 Jun;45(4):361-379. doi: 10.1111/nan.12514. Epub 2018 Aug 29.
|
| 175 |
Mitochondrial SIRT3 and neurodegenerative brain disorders.J Chem Neuroanat. 2019 Jan;95:43-53. doi: 10.1016/j.jchemneu.2017.11.009. Epub 2017 Nov 9.
|
| 176 |
Expression of RNAs Coding for Metal Transporters in Blood of Patients with Huntington's Disease.Neurochem Res. 2016 Feb;41(1-2):101-6. doi: 10.1007/s11064-015-1737-4. Epub 2015 Oct 15.
|
| 177 |
Enhanced Na(+) -K(+) -2Cl(-) cotransporter 1 underlies motor dysfunction in huntington's disease.Mov Disord. 2019 Jun;34(6):845-857. doi: 10.1002/mds.27651. Epub 2019 Mar 6.
|
| 178 |
Restoring GABAergic inhibition rescues memory deficits in a Huntington's disease mouse model.Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1618-E1626. doi: 10.1073/pnas.1716871115. Epub 2018 Jan 30.
|
| 179 |
Deutetrabenazine for the treatment of Huntington's chorea.Expert Rev Neurother. 2018 Aug;18(8):625-631. doi: 10.1080/14737175.2018.1500178. Epub 2018 Jul 17.
|
| 180 |
Aberrant Rab11-dependent trafficking of the neuronal glutamate transporter EAAC1 causes oxidative stress and cell death in Huntington's disease.J Neurosci. 2010 Mar 31;30(13):4552-61. doi: 10.1523/JNEUROSCI.5865-09.2010.
|
| 181 |
Post-translational Regulation of GLT-1 in Neurological Diseases and Its Potential as an Effective Therapeutic Target.Front Mol Neurosci. 2019 Jul 9;12:164. doi: 10.3389/fnmol.2019.00164. eCollection 2019.
|
| 182 |
Striatal excitatory amino acid transporter transcript expression in schizophrenia, bipolar disorder, and major depressive disorder.Neuropsychopharmacology. 2002 Mar;26(3):368-75. doi: 10.1016/S0893-133X(01)00370-0.
|
| 183 |
Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis.Am J Kidney Dis. 2004 Jun;43(6):1030-9. doi: 10.1053/j.ajkd.2004.02.016.
|
| 184 |
Mesenchymal stem cells alleviate AQP-4-dependent glymphatic dysfunction and improve brain distribution of antisense oligonucleotides in BACHD mice.Stem Cells. 2020 Feb;38(2):218-230. doi: 10.1002/stem.3103. Epub 2019 Oct 31.
|
| 185 |
Influence of SLCO1B3 gene polymorphism on the pharmacokinetics of digoxin in terminal renal failure.Drug Metab Pharmacokinet. 2008;23(6):406-11. doi: 10.2133/dmpk.23.406.
|
| 186 |
Co-occurrence of mixed proteinopathies in late-stage Huntington's disease.Acta Neuropathol. 2018 Feb;135(2):249-265. doi: 10.1007/s00401-017-1786-7. Epub 2017 Nov 13.
|
| 187 |
The therapeutic potential of intrabodies in neurologic disorders: focus on Huntington and Parkinson diseases.BioDrugs. 2006;20(6):327-33. doi: 10.2165/00063030-200620060-00002.
|
| 188 |
Mutant Huntingtin Affects Diabetes and Alzheimer's Markers in Human and Cell Models of Huntington's Disease.Cells. 2019 Aug 23;8(9):962. doi: 10.3390/cells8090962.
|
| 189 |
Inhibiting sphingosine kinase 2 mitigates mutant Huntingtin-induced neurodegeneration in neuron models of Huntington disease.Hum Mol Genet. 2017 Apr 1;26(7):1305-1317. doi: 10.1093/hmg/ddx046.
|
| 190 |
Striatal GABAergic interneuron dysfunction in the Q175 mouse model of Huntington's disease.Eur J Neurosci. 2019 Jan;49(1):79-93. doi: 10.1111/ejn.14283. Epub 2018 Dec 10.
|
| 191 |
Studies of a DNA marker (G8) genetically linked to Huntington disease in British families.Hum Genet. 1986 Aug;73(4):333-9. doi: 10.1007/BF00279096.
|
| 192 |
Mutant Huntingtin Causes a Selective Decrease in the Expression of Synaptic Vesicle Protein 2C.Neurosci Bull. 2018 Oct;34(5):747-758. doi: 10.1007/s12264-018-0230-x. Epub 2018 Apr 30.
|
| 193 |
Cystamine and cysteamine increase brain levels of BDNF in Huntington disease via HSJ1b and transglutaminase.J Clin Invest. 2006 May;116(5):1410-24. doi: 10.1172/JCI27607. Epub 2006 Apr 6.
|
| 194 |
Validating Body Fat Assessment by Bioelectric Impedance Spectroscopy in Taiwanese Hemodialysis Patients.J Ren Nutr. 2017 Jan;27(1):37-44. doi: 10.1053/j.jrn.2016.08.003. Epub 2016 Sep 22.
|
| 195 |
Cdc42-interacting protein 4 binds to huntingtin: neuropathologic and biological evidence for a role in Huntington's disease.Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2712-7. doi: 10.1073/pnas.0437967100. Epub 2003 Feb 25.
|
| 196 |
Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease.Brain. 2015 Oct;138(Pt 10):3030-47. doi: 10.1093/brain/awv188. Epub 2015 Jun 30.
|
| 197 |
Dietary Tryptophan Induces Opposite Health-Related Responses in the Senegalese Sole (Solea senegalensis) Reared at Low or High Stocking Densities With Implications in Disease Resistance.Front Physiol. 2019 May 1;10:508. doi: 10.3389/fphys.2019.00508. eCollection 2019.
|
| 198 |
A two years longitudinal study of a transgenic Huntington disease monkey.BMC Neurosci. 2014 Mar 3;15:36. doi: 10.1186/1471-2202-15-36.
|
| 199 |
Polymorphism of HD and UCHL-1 genes in Huntington's disease.J Clin Neurosci. 2009 Nov;16(11):1473-7. doi: 10.1016/j.jocn.2009.03.027. Epub 2009 Aug 14.
|
| 200 |
Impairment of PGC-1alpha expression, neuropathology and hepatic steatosis in a transgenic mouse model of Huntington's disease following chronic energy deprivation.Hum Mol Genet. 2010 Aug 15;19(16):3190-205. doi: 10.1093/hmg/ddq229. Epub 2010 Jun 7.
|
| 201 |
ATAD3A oligomerization causes neurodegeneration by coupling mitochondrial fragmentation and bioenergetics defects.Nat Commun. 2019 Mar 26;10(1):1371. doi: 10.1038/s41467-019-09291-x.
|
| 202 |
VCP cooperates with UBXD1 to degrade mitochondrial outer membrane protein MCL1 in model of Huntington's disease.Biochim Biophys Acta Mol Basis Dis. 2017 Feb;1863(2):552-559. doi: 10.1016/j.bbadis.2016.11.026. Epub 2016 Nov 29.
|
| 203 |
Decreased VIP and VPAC2 receptor expression in the biological clock of the R6/2 Huntington's disease mouse.J Mol Neurosci. 2007;31(2):139-48. doi: 10.1385/jmn/31:02:139.
|
| 204 |
Epigenetic and transcriptional modulation of WDR5, a chromatin remodeling protein, in Huntington's disease human induced pluripotent stem cell (hiPSC) model.Mol Cell Neurosci. 2017 Jul;82:46-57. doi: 10.1016/j.mcn.2017.04.013. Epub 2017 May 2.
|
| 205 |
Atypical ubiquitination by E3 ligase WWP1 inhibits the proteasome-mediated degradation of mutant huntingtin.Brain Res. 2016 Jul 15;1643:103-12. doi: 10.1016/j.brainres.2016.03.027. Epub 2016 Apr 21.
|
| 206 |
Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
|
| 207 |
Familial dyskinesia and facial myokymia (FDFM): a novel movement disorder.Ann Neurol. 2001 Apr;49(4):486-92.
|
| 208 |
Investigating the Contribution of NPSR1, IL-6 and BDNF Polymorphisms to Depressive and Anxiety Symptoms in Hemodialysis Patients.Prog Neuropsychopharmacol Biol Psychiatry. 2019 Aug 30;94:109657. doi: 10.1016/j.pnpbp.2019.109657. Epub 2019 May 25.
|
| 209 |
Rab7 may be a novel therapeutic target for neurologic diseases as a key regulator in autophagy.J Neurosci Res. 2017 Oct;95(10):1993-2004. doi: 10.1002/jnr.24034. Epub 2017 Feb 10.
|
| 210 |
Aerobic glycolysis in amyotrophic lateral sclerosis and Huntington's disease.Rev Neurosci. 2018 Jul 26;29(5):547-555. doi: 10.1515/revneuro-2017-0075.
|
| 211 |
Brain mitochondrial iron accumulates in Huntington's disease, mediates mitochondrial dysfunction, and can be removed pharmacologically.Free Radic Biol Med. 2018 May 20;120:317-329. doi: 10.1016/j.freeradbiomed.2018.04.002. Epub 2018 Apr 4.
|
| 212 |
Altered lactate metabolism in Huntington's disease is dependent on GLUT3 expression.CNS Neurosci Ther. 2018 Apr;24(4):343-352. doi: 10.1111/cns.12837.
|
| 213 |
Na+/H+ exchangers induce autophagy in neurons and inhibit polyglutamine-induced aggregate formation.PLoS One. 2013 Nov 21;8(11):e81313. doi: 10.1371/journal.pone.0081313. eCollection 2013.
|
| 214 |
Characterization of Endocannabinoid-Metabolizing Enzymes in Human Peripheral Blood Mononuclear Cells under Inflammatory Conditions.Molecules. 2018 Dec 1;23(12):3167. doi: 10.3390/molecules23123167.
|
| 215 |
The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau).Autophagy. 2019 Apr;15(4):583-598. doi: 10.1080/15548627.2018.1532258. Epub 2018 Oct 16.
|
| 216 |
Synthetic lethal screening in the mammalian central nervous system identifies Gpx6 as a modulator of Huntington's disease.Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):268-72. doi: 10.1073/pnas.1417231112. Epub 2014 Dec 22.
|
| 217 |
Glutathione S-Transferase Omega 1 variation does not influence age at onset of Huntington's disease.BMC Med Genet. 2004 Mar 24;5:7. doi: 10.1186/1471-2350-5-7.
|
| 218 |
Huntington's disease: Neural dysfunction linked to inositol polyphosphate multikinase.Proc Natl Acad Sci U S A. 2015 Aug 4;112(31):9751-6. doi: 10.1073/pnas.1511810112. Epub 2015 Jul 20.
|
| 219 |
Dissection and Preparation of Human Primary Fetal Ganglionic Eminence Tissue for Research and Clinical Applications.Methods Mol Biol. 2018;1780:573-583. doi: 10.1007/978-1-4939-7825-0_26.
|
| 220 |
Olfactory abnormalities in Huntington's disease: decreased plasticity in the primary olfactory cortex of R6/1 transgenic mice and reduced olfactory discrimination in patients.Brain Res. 2007 Jun 2;1151:219-26. doi: 10.1016/j.brainres.2007.03.018. Epub 2007 Mar 12.
|
| 221 |
Importance of psychiatric examination in predictive genetic testing for Huntington disease.Neurol Neurochir Pol. 2013 Nov-Dec;47(6):534-41. doi: 10.5114/ninp.2013.39070.
|
| 222 |
Mutant huntingtin protein: a substrate for transglutaminase 1, 2, and 3.J Neuropathol Exp Neurol. 2005 Jan;64(1):58-65. doi: 10.1093/jnen/64.1.58.
|
| 223 |
Huntingtin protein interactions altered by polyglutamine expansion as determined by quantitative proteomic analysis.Cell Cycle. 2012 May 15;11(10):2006-21. doi: 10.4161/cc.20423. Epub 2012 May 15.
|
| 224 |
Cullin-4B E3 ubiquitin ligase mediates Apaf-1 ubiquitination to regulate caspase-9 activity.PLoS One. 2019 Jul 22;14(7):e0219782. doi: 10.1371/journal.pone.0219782. eCollection 2019.
|
| 225 |
Pathogenesis of SCA3 and implications for other polyglutamine diseases.Neurobiol Dis. 2020 Feb;134:104635. doi: 10.1016/j.nbd.2019.104635. Epub 2019 Oct 24.
|
| 226 |
Forecast post-dialysis blood pressure in hemodialysis patients with intradialytic hypertension.Clin Exp Hypertens. 2019;41(6):571-576. doi: 10.1080/10641963.2018.1523916. Epub 2018 Oct 16.
|
| 227 |
Dysregulation of core components of SCF complex in poly-glutamine disorders.Cell Death Dis. 2012 Nov 22;3(11):e428. doi: 10.1038/cddis.2012.166.
|
| 228 |
Serum Erythroferrone Levels Associate with Mortality and Cardiovascular Events in Hemodialysis and in CKD Patients: A Two Cohorts Study.J Clin Med. 2019 Apr 16;8(4):523. doi: 10.3390/jcm8040523.
|
| 229 |
Fibroblast growth factor 9 activates anti-oxidative functions of Nrf2 through ERK signalling in striatal cell models of Huntington's disease.Free Radic Biol Med. 2019 Jan;130:256-266. doi: 10.1016/j.freeradbiomed.2018.10.455. Epub 2018 Nov 2.
|
| 230 |
Structure of FBP11 WW1-PL ligand complex reveals the mechanism of proline-rich ligand recognition by group II/III WW domains.J Biol Chem. 2006 Dec 29;281(52):40321-9. doi: 10.1074/jbc.M609321200. Epub 2006 Oct 24.
|
| 231 |
Contribution of Common Variants in GABRG2, RELN and NRG3 and Interaction Networks to the Risk of Hirschsprung Disease.Cell Physiol Biochem. 2016;40(3-4):509-526. doi: 10.1159/000452565. Epub 2016 Nov 25.
|
| 232 |
SUMO-Targeted Ubiquitin Ligases (STUbLs) Reduce the Toxicity and Abnormal Transcriptional Activity Associated With a Mutant, Aggregation-Prone Fragment of Huntingtin.Front Genet. 2018 Sep 18;9:379. doi: 10.3389/fgene.2018.00379. eCollection 2018.
|
| 233 |
Transcriptional Elongation Regulator 1 Affects Transcription and Splicing of Genes Associated with Cellular Morphology and Cytoskeleton Dynamics and Is Required for Neurite Outgrowth in Neuroblastoma Cells and Primary Neuronal Cultures.Mol Neurobiol. 2017 Dec;54(10):7808-7823. doi: 10.1007/s12035-016-0284-6. Epub 2016 Nov 14.
|
| 234 |
Comparative transcriptomics of choroid plexus in Alzheimer's disease, frontotemporal dementia and Huntington's disease: implications for CSF homeostasis.Fluids Barriers CNS. 2018 May 31;15(1):18. doi: 10.1186/s12987-018-0102-9.
|
| 235 |
Inositol hexakisphosphate kinases induce cell death in Huntington disease.J Biol Chem. 2011 Jul 29;286(30):26680-6. doi: 10.1074/jbc.M111.220749. Epub 2011 Jun 7.
|
| 236 |
Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients.Biol Trace Elem Res. 2020 Jan;193(1):14-22. doi: 10.1007/s12011-019-01685-8. Epub 2019 Mar 7.
|
| 237 |
Mutant huntingtin inhibits the mitochondrial unfolded protein response by impairing ABCB10 mRNA stability.Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1428-1435. doi: 10.1016/j.bbadis.2019.02.015. Epub 2019 Feb 23.
|
| 238 |
Acyl-CoA-Binding Domain-Containing 3 (ACBD3; PAP7; GCP60): A Multi-Functional Membrane Domain Organizer.Int J Mol Sci. 2019 Apr 24;20(8):2028. doi: 10.3390/ijms20082028.
|
| 239 |
Mutant huntingtin induces iron overload via up-regulating IRP1 in Huntington's disease.Cell Biosci. 2018 Jul 4;8:41. doi: 10.1186/s13578-018-0239-x. eCollection 2018.
|
| 240 |
Predictive testing for Huntington's disease with use of a linked DNA marker.N Engl J Med. 1988 Mar 3;318(9):535-42. doi: 10.1056/NEJM198803033180903.
|
| 241 |
Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study.Lancet Neurol. 2017 Sep;16(9):701-711. doi: 10.1016/S1474-4422(17)30161-8. Epub 2017 Jun 20.
|
| 242 |
Polymorphisms and expression of genes encoding Argonautes 1 and 2 in autoimmune thyroid diseases.Autoimmunity. 2018 Feb;51(1):35-42. doi: 10.1080/08916934.2017.1416468. Epub 2017 Dec 19.
|
| 243 |
Interaction of the nuclear matrix protein NAKAP with HypA and huntingtin: implications for nuclear toxicity in Huntington's disease pathogenesis.Neuromolecular Med. 2005;7(4):297-310. doi: 10.1385/NMM:7:4:297.
|
| 244 |
Genomic organization and complete sequence of the human gene encoding the beta-subunit of the cGMP phosphodiesterase and its localisation to 4p 16.3.Nucleic Acids Res. 1991 Nov 25;19(22):6263-8. doi: 10.1093/nar/19.22.6263.
|
| 245 |
ADP-ribosylation factor guanine nucleotide-exchange factor 2 (ARFGEF2): a new potential biomarker in Huntington's disease.J Int Med Res. 2010 Sep-Oct;38(5):1653-62. doi: 10.1177/147323001003800510.
|
| 246 |
Arfaptin 2 regulates the aggregation of mutant huntingtin protein.Nat Cell Biol. 2002 Mar;4(3):240-5. doi: 10.1038/ncb761.
|
| 247 |
The neuroprotective transcription factor ATF5 is decreased and sequestered into polyglutamine inclusions in Huntington's disease.Acta Neuropathol. 2017 Dec;134(6):839-850. doi: 10.1007/s00401-017-1770-2. Epub 2017 Aug 31.
|
| 248 |
Inhibition of DREAM-ATF6 interaction delays onset of cognition deficit in a mouse model of Huntington's disease.Mol Brain. 2018 Mar 9;11(1):13. doi: 10.1186/s13041-018-0359-6.
|
| 249 |
Mechanism suppressing H3K9 trimethylation in pluripotent stem cells and its demise by polyQ-expanded huntingtin mutations.Hum Mol Genet. 2018 Dec 1;27(23):4117-4134. doi: 10.1093/hmg/ddy304.
|
| 250 |
Molecular Mechanisms and Therapeutic Strategies in Spinocerebellar Ataxia Type 7.Adv Exp Med Biol. 2018;1049:197-218. doi: 10.1007/978-3-319-71779-1_9.
|
| 251 |
CTIP2-Regulated Reduction in PKA-Dependent DARPP32 Phosphorylation in Human Medium Spiny Neurons: Implications for Huntington Disease.Stem Cell Reports. 2019 Sep 10;13(3):448-457. doi: 10.1016/j.stemcr.2019.07.015. Epub 2019 Aug 22.
|
| 252 |
CAG trinucleotide RNA repeats interact with RNA-binding proteins.Am J Hum Genet. 1996 Sep;59(3):561-9.
|
| 253 |
Mutant huntingtin-impaired degradation of beta-catenin causes neurotoxicity in Huntington's disease.EMBO J. 2010 Jul 21;29(14):2433-45. doi: 10.1038/emboj.2010.117. Epub 2010 Jun 8.
|
| 254 |
The sigma-1 receptor mediates the beneficial effects of pridopidine in a mouse model of Huntington disease.Neurobiol Dis. 2017 Jan;97(Pt A):46-59. doi: 10.1016/j.nbd.2016.10.006. Epub 2016 Nov 3.
|
| 255 |
Modulation of age at onset of Huntington disease patients by variations in TP53 and human caspase activated DNase (hCAD) genes.Neurosci Lett. 2005 Feb 10;374(2):81-6. doi: 10.1016/j.neulet.2004.10.018. Epub 2004 Dec 23.
|
| 256 |
Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.Neurobiol Dis. 2017 Dec;108:29-44. doi: 10.1016/j.nbd.2017.07.020. Epub 2017 Jul 27.
|
| 257 |
Calpastatin ablation aggravates the molecular phenotype in cell and animal models of Huntington disease.Neuropharmacology. 2018 May 1;133:94-106. doi: 10.1016/j.neuropharm.2018.01.022.
|
| 258 |
The cytokine and endocannabinoid systems are co-regulated by NF-B p65/RelA in cell culture and transgenic mouse models of Huntington's disease and in striatal tissue from Huntington's disease patients.J Neuroimmunol. 2014 Feb 15;267(1-2):61-72. doi: 10.1016/j.jneuroim.2013.12.008. Epub 2013 Dec 12.
|
| 259 |
Sequence analysis of the CCG polymorphic region adjacent to the CAG triplet repeat of the HD gene in normal and HD chromosomes.J Med Genet. 1995 May;32(5):399-400. doi: 10.1136/jmg.32.5.399.
|
| 260 |
De novo Synthesis of Sphingolipids Is Defective in Experimental Models of Huntington's Disease.Front Neurosci. 2017 Dec 19;11:698. doi: 10.3389/fnins.2017.00698. eCollection 2017.
|
| 261 |
MAP2 Splicing is Altered in Huntington's Disease.Brain Pathol. 2017 Mar;27(2):181-189. doi: 10.1111/bpa.12387. Epub 2016 Jul 7.
|
| 262 |
Early transcriptional changes linked to naturally occurring Huntington's disease mutations in neural derivatives of human embryonic stem cells.Hum Mol Genet. 2012 Sep 1;21(17):3883-95. doi: 10.1093/hmg/dds216. Epub 2012 Jun 7.
|
| 263 |
Cerebrospinal fluid sCD27 levels indicate active T cell-mediated inflammation in premanifest Huntington's disease.PLoS One. 2018 Feb 23;13(2):e0193492. doi: 10.1371/journal.pone.0193492. eCollection 2018.
|
| 264 |
Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage.Hum Mol Genet. 2007 Aug 1;16(15):1845-61. doi: 10.1093/hmg/ddm133. Epub 2007 May 21.
|
| 265 |
Enhancement of brain-type creatine kinase activity ameliorates neuronal deficits in Huntington's disease.Biochim Biophys Acta. 2013 Jun;1832(6):742-53. doi: 10.1016/j.bbadis.2013.02.006. Epub 2013 Feb 15.
|
| 266 |
Factors influencing survival time of hemodialysis patients; time to event analysis using parametric models: a cohort study.BMC Nephrol. 2019 Jun 11;20(1):215. doi: 10.1186/s12882-019-1382-2.
|
| 267 |
PRMT5- mediated symmetric arginine dimethylation is attenuated by mutant huntingtin and is impaired in Huntington's disease (HD).Cell Cycle. 2015;14(11):1716-29. doi: 10.1080/15384101.2015.1033595.
|
| 268 |
Hemodialysis patient characteristics associated with better experience as measured by the In-center Hemodialysis Consumer Assessment of Healthcare Providers and Systems (ICH CAHPS) survey.BMC Nephrol. 2018 Nov 28;19(1):340. doi: 10.1186/s12882-018-1147-3.
|
| 269 |
Clorgyline-mediated reversal of neurological deficits in a Complexin 2 knockout mouse.Hum Mol Genet. 2010 Sep 1;19(17):3402-12. doi: 10.1093/hmg/ddq252. Epub 2010 Jun 28.
|
| 270 |
Oxidative stress and plasma aminopeptidase activity in Huntington's disease.J Neural Transm (Vienna). 2010 Mar;117(3):325-32. doi: 10.1007/s00702-009-0364-0. Epub 2010 Jan 22.
|
| 271 |
Cockayne syndrome B protein antagonizes OGG1 in modulating CAG repeat length in vivo.Aging (Albany NY). 2011 May;3(5):509-14. doi: 10.18632/aging.100324.
|
| 272 |
A small molecule TrkB ligand reduces motor impairment and neuropathology in R6/2 and BACHD mouse models of Huntington's disease.J Neurosci. 2013 Nov 27;33(48):18712-27. doi: 10.1523/JNEUROSCI.1310-13.2013.
|
| 273 |
Reduced pro-inflammatory responses to Staphylococcus aureus bloodstream infection and low prevalence of enterotoxin genes in isolates from patients on haemodialysis.Eur J Clin Microbiol Infect Dis. 2017 Jan;36(1):33-42. doi: 10.1007/s10096-016-2767-9. Epub 2016 Sep 9.
|
| 274 |
Transcriptomics of maternal and fetal membranes can discriminate between gestational-age matched preterm neonates with and without cognitive impairment diagnosed at 18-24 months.PLoS One. 2015 Mar 30;10(3):e0118573. doi: 10.1371/journal.pone.0118573. eCollection 2015.
|
| 275 |
HIPK3 modulates autophagy and HTT protein levels in neuronal and mouse models of Huntington disease.Autophagy. 2018;14(1):169-170. doi: 10.1080/15548627.2017.1393130. Epub 2018 Jan 29.
|
| 276 |
Inhibition of lipid signaling enzyme diacylglycerol kinase epsilon attenuates mutant huntingtin toxicity.J Biol Chem. 2012 Jun 15;287(25):21204-13. doi: 10.1074/jbc.M111.321661. Epub 2012 Apr 16.
|
| 277 |
Aggregation of scaffolding protein DISC1 dysregulates phosphodiesterase 4 in Huntington's disease.J Clin Invest. 2017 Apr 3;127(4):1438-1450. doi: 10.1172/JCI85594. Epub 2017 Mar 6.
|
| 278 |
SAP97-mediated rescue of NMDA receptor surface distribution in a neuronal model of Huntington's disease.Hippocampus. 2018 Oct;28(10):707-723. doi: 10.1002/hipo.22995.
|
| 279 |
Role of Dynein Axonemal Heavy Chain 6 Gene Expression as a Possible Biomarker for Huntington's Disease: a Translational Study.J Mol Neurosci. 2017 Dec;63(3-4):342-348. doi: 10.1007/s12031-017-0984-z. Epub 2017 Oct 10.
|
| 280 |
Effects of heat shock, heat shock protein 40 (HDJ-2), and proteasome inhibition on protein aggregation in cellular models of Huntington's disease.Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2898-903. doi: 10.1073/pnas.97.6.2898.
|
| 281 |
Suppression of protein aggregation by chaperone modification of high molecular weight complexes.Brain. 2012 Apr;135(Pt 4):1180-96. doi: 10.1093/brain/aws022. Epub 2012 Mar 6.
|
| 282 |
Astrocytic expression of the chaperone DNAJB6 results in non-cell autonomous protection in Huntington's disease.Neurobiol Dis. 2019 Apr;124:108-117. doi: 10.1016/j.nbd.2018.10.017. Epub 2018 Nov 5.
|
| 283 |
Interdigitated deletion complexes on mouse chromosome 5 induced by irradiation of embryonic stem cells.Genome Res. 2000 Jul;10(7):1043-50. doi: 10.1101/gr.10.7.1043.
|
| 284 |
DICER and DROSHA gene expression and polymorphisms in autoimmune thyroid diseases.Autoimmunity. 2016 Dec;49(8):514-522. doi: 10.1080/08916934.2016.1230846. Epub 2016 Nov 3.
|
| 285 |
Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity.J Neurosci. 2008 Sep 3;28(36):9013-20. doi: 10.1523/JNEUROSCI.2747-08.2008.
|
| 286 |
Early epigenomic and transcriptional changes reveal Elk-1 transcription factor as a therapeutic target in Huntington's disease.Proc Natl Acad Sci U S A. 2019 Dec 3;116(49):24840-24851. doi: 10.1073/pnas.1908113116. Epub 2019 Nov 19.
|
| 287 |
Antibiotic Prophylaxis for Melioidosis in Patients Receiving Hemodialysis in the Tropics? One Size Does Not Fit All.Am J Trop Med Hyg. 2018 Sep;99(3):597-600. doi: 10.4269/ajtmh.18-0421. Epub 2018 Jul 12.
|
| 288 |
Quantitative proteomics reveals EVA1A-related proteins involved in neuronal differentiation.Proteomics. 2017 Mar;17(5). doi: 10.1002/pmic.201600294. Epub 2017 Feb 21.
|
| 289 |
Design and characterization of mutant and wildtype huntingtin proteins produced from a toolkit of scalable eukaryotic expression systems.J Biol Chem. 2019 Apr 26;294(17):6986-7001. doi: 10.1074/jbc.RA118.007204. Epub 2019 Mar 6.
|
| 290 |
Neurological disease-associated autoantibodies against an unknown protein encoded by a RES4-22 homologous gene.Scand J Immunol. 2001 Feb;53(2):204-8. doi: 10.1046/j.1365-3083.2001.00839.x.
|
| 291 |
Variation in DNA Repair System Gene as an Additional Modifier of Age at Onset in Spinocerebellar Ataxia Type 3/Machado-Joseph Disease.Neuromolecular Med. 2020 Mar;22(1):133-138. doi: 10.1007/s12017-019-08572-4. Epub 2019 Oct 5.
|
| 292 |
Nuclease-deficient FEN-1 blocks Rad51/BRCA1-mediated repair and causes trinucleotide repeat instability.Mol Cell Biol. 2003 Sep;23(17):6063-74. doi: 10.1128/MCB.23.17.6063-6074.2003.
|
| 293 |
Drp1/Fis1-mediated mitochondrial fragmentation leads to lysosomal dysfunction in cardiac models of Huntington's disease.J Mol Cell Cardiol. 2019 Feb;127:125-133. doi: 10.1016/j.yjmcc.2018.12.004. Epub 2018 Dec 11.
|
| 294 |
NMR Spectroscopy-based Metabolomics of Drosophila Model of Huntington's Disease Suggests Altered Cell Energetics.J Proteome Res. 2017 Oct 6;16(10):3863-3872. doi: 10.1021/acs.jproteome.7b00491. Epub 2017 Sep 26.
|
| 295 |
FOXOs modulate proteasome activity in human-induced pluripotent stem cells of Huntington's disease and their derived neural cells.Hum Mol Genet. 2017 Nov 15;26(22):4416-4428. doi: 10.1093/hmg/ddx327.
|
| 296 |
Revealing Clusters of Connected Pathways Through Multisource Data Integration in Huntington's Disease and Spastic Ataxia.IEEE J Biomed Health Inform. 2019 Jan;23(1):26-37. doi: 10.1109/JBHI.2018.2865569. Epub 2018 Aug 30.
|
| 297 |
A protein interaction network links GIT1, an enhancer of huntingtin aggregation, to Huntington's disease.Mol Cell. 2004 Sep 24;15(6):853-65. doi: 10.1016/j.molcel.2004.09.016.
|
| 298 |
RNAi-Based GluN3A Silencing Prevents and Reverses Disease Phenotypes Induced by Mutant huntingtin.Mol Ther. 2018 Aug 1;26(8):1965-1972. doi: 10.1016/j.ymthe.2018.05.013. Epub 2018 Jun 15.
|
| 299 |
Altered hypothalamic protein expression in a rat model of Huntington's disease.PLoS One. 2012;7(10):e47240. doi: 10.1371/journal.pone.0047240. Epub 2012 Oct 18.
|
| 300 |
DNA damage signatures in peripheral blood cells as biomarkers in prodromal huntington disease.Ann Neurol. 2019 Feb;85(2):296-301. doi: 10.1002/ana.25393. Epub 2019 Jan 13.
|
| 301 |
Indexing disease progression at study entry with individuals at-risk for Huntington disease.Am J Med Genet B Neuropsychiatr Genet. 2011 Dec;156B(7):751-63. doi: 10.1002/ajmg.b.31232. Epub 2011 Aug 19.
|
| 302 |
HACE1 is essential for astrocyte mitochondrial function and influences Huntington disease phenotypes in vivo.Hum Mol Genet. 2018 Jan 15;27(2):239-253. doi: 10.1093/hmg/ddx394.
|
| 303 |
Replacement of charged and polar residues in the coiled-coiled interface of huntingtin-interacting protein 1 (HIP1) causes aggregation and cell death.FEBS Lett. 2012 Sep 21;586(19):3030-6. doi: 10.1016/j.febslet.2012.07.011. Epub 2012 Jul 23.
|
| 304 |
Relationship of serum haemojuvelin and hepcidin levels with iron level and erythropoietin requirement in prevalent hepatitis C virus positive haemodialysis patients.Nephrology (Carlton). 2018 Apr;23(4):323-330. doi: 10.1111/nep.13010.
|
| 305 |
Diminished hippocalcin expression in Huntington's disease brain does not account for increased striatal neuron vulnerability as assessed in primary neurons.J Neurochem. 2009 Oct;111(2):460-72. doi: 10.1111/j.1471-4159.2009.06344.x. Epub 2009 Aug 17.
|
| 306 |
Identification of genes associated with the effect of inflammation on the neurotransmission of vascular smooth muscle cell.Exp Ther Med. 2017 Apr;13(4):1303-1312. doi: 10.3892/etm.2017.4138. Epub 2017 Feb 21.
|
| 307 |
Effects of Synbiotics and Probiotics Supplementation on Serum Levels of Endotoxin, Heat Shock Protein 70 Antibodies and Inflammatory Markers in Hemodialysis Patients: a Randomized Double-Blinded Controlled Trial.Probiotics Antimicrob Proteins. 2020 Mar;12(1):144-151. doi: 10.1007/s12602-018-9509-5.
|
| 308 |
Omi / HtrA2 is relevant to the selective vulnerability of striatal neurons in Huntington's disease.Eur J Neurosci. 2008 Jul;28(1):30-40. doi: 10.1111/j.1460-9568.2008.06323.x.
|
| 309 |
Chaperone-like protein HYPK and its interacting partners augment autophagy.Eur J Cell Biol. 2016 Jun-Jul;95(6-7):182-94. doi: 10.1016/j.ejcb.2016.03.003. Epub 2016 Apr 1.
|
| 310 |
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood.Proc Natl Acad Sci U S A. 2007 Sep 4;104(36):14424-9. doi: 10.1073/pnas.0703652104. Epub 2007 Aug 27.
|
| 311 |
Regulation of RE1 protein silencing transcription factor (REST) expression by HIP1 protein interactor (HIPPI).J Biol Chem. 2011 Sep 30;286(39):33759-69. doi: 10.1074/jbc.M111.265173. Epub 2011 Aug 6.
|
| 312 |
Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design.Curr Neuropharmacol. 2018;16(6):649-663. doi: 10.2174/1570159X16666180315142137.
|
| 313 |
Increased Act1/IL-17R expression in Hirschsprung's disease.Pediatr Surg Int. 2016 Dec;32(12):1201-1207. doi: 10.1007/s00383-016-3980-4. Epub 2016 Sep 22.
|
| 314 |
IKK and mutant huntingtin interactions regulate the expression of IL-34: implications for microglial-mediated neurodegeneration in HD.Hum Mol Genet. 2017 Nov 1;26(21):4267-4277. doi: 10.1093/hmg/ddx315.
|
| 315 |
The role of mitofilin in left ventricular hypertrophy in hemodialysis patients.Ren Fail. 2018 Nov;40(1):252-258. doi: 10.1080/0886022X.2018.1456455.
|
| 316 |
Kalirin, a key player in synapse formation, is implicated in human diseases.Neural Plast. 2012;2012:728161. doi: 10.1155/2012/728161. Epub 2012 Apr 3.
|
| 317 |
Targeting the neuronal calcium sensor DREAM with small-molecules for Huntington's disease treatment.Sci Rep. 2019 May 13;9(1):7260. doi: 10.1038/s41598-019-43677-7.
|
| 318 |
HDAC inhibition imparts beneficial transgenerational effects in Huntington's disease mice via altered DNA and histone methylation.Proc Natl Acad Sci U S A. 2015 Jan 6;112(1):E56-64. doi: 10.1073/pnas.1415195112. Epub 2014 Dec 22.
|
| 319 |
SNP-guided microRNA maps (MirMaps) of 16 common human disorders identify a clinically accessible therapy reversing transcriptional aberrations of nuclear import and inflammasome pathways.Cell Cycle. 2008 Nov 15;7(22):3564-76. doi: 10.4161/cc.7.22.7073. Epub 2008 Nov 26.
|
| 320 |
Reduced brain-derived neurotrophic factor (BDNF) mRNA expression and presence of BDNF-immunoreactive granules in the spinocerebellar ataxia type 6 (SCA6) cerebellum.Neuropathology. 2012 Dec;32(6):595-603. doi: 10.1111/j.1440-1789.2012.01302.x. Epub 2012 Mar 7.
|
| 321 |
Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouse.Proc Natl Acad Sci U S A. 2011 Oct 11;108(41):17141-6. doi: 10.1073/pnas.1104409108. Epub 2011 Oct 3.
|
| 322 |
Blocking the association of HDAC4 with MAP1S accelerates autophagy clearance of mutant Huntingtin.Aging (Albany NY). 2015 Oct;7(10):839-53. doi: 10.18632/aging.100818.
|
| 323 |
Triggering of neuronal cell death by accumulation of activated SEK1 on nuclear polyglutamine aggregations in PML bodies.Genes Cells. 1999 Dec;4(12):743-56. doi: 10.1046/j.1365-2443.1999.00294.x.
|
| 324 |
Hsa-miR-34b is a plasma-stable microRNA that is elevated in pre-manifest Huntington's disease.Hum Mol Genet. 2011 Jun 1;20(11):2225-37. doi: 10.1093/hmg/ddr111. Epub 2011 Mar 19.
|
| 325 |
Mild cognitive impairment and dementia in motor manifest Huntington's disease: Classification and prevalence.J Neurol Sci. 2020 Jan 15;408:116523. doi: 10.1016/j.jns.2019.116523. Epub 2019 Oct 15.
|
| 326 |
Encapsulated cell-based biodelivery of meteorin is neuroprotective in the quinolinic acid rat model of neurodegenerative disease.Restor Neurol Neurosci. 2012;30(3):225-36. doi: 10.3233/RNN-2012-110199.
|
| 327 |
Mismatch repair genes Mlh1 and Mlh3 modify CAG instability in Huntington's disease mice: genome-wide and candidate approaches.PLoS Genet. 2013 Oct;9(10):e1003930. doi: 10.1371/journal.pgen.1003930. Epub 2013 Oct 31.
|
| 328 |
Type 2 Transglutaminase, mitochondria and Huntington's disease: menage a trois.Mitochondrion. 2014 Nov;19 Pt A:97-104. doi: 10.1016/j.mito.2014.09.008. Epub 2014 Sep 28.
|
| 329 |
Receptor for Advanced Glycation End Products (RAGE) is Expressed Predominantly in Medium Spiny Neurons of tgHD Rat Striatum.Neuroscience. 2018 Jun 1;380:146-151. doi: 10.1016/j.neuroscience.2018.03.042. Epub 2018 Apr 4.
|
| 330 |
MSH3 modifies somatic instability and disease severity in Huntington's and myotonic dystrophy type 1.Brain. 2019 Jun 19;142(7):1876-86. doi: 10.1093/brain/awz115. Online ahead of print.
|
| 331 |
Genetically-directed Sparse Neuronal Labeling in BAC Transgenic Mice through Mononucleotide Repeat Frameshift.Sci Rep. 2017 Mar 8;7:43915. doi: 10.1038/srep43915.
|
| 332 |
Evidence for a modifier of onset age in Huntington disease linked to the HD gene in 4p16.Neurogenetics. 2004 Jun;5(2):109-14. doi: 10.1007/s10048-004-0175-2. Epub 2004 Mar 17.
|
| 333 |
TT virus infection and genotype distribution in blood donors and a group of patients from Turkey.Infection. 2002 Oct;30(5):299-302. doi: 10.1007/s15010-002-2185-z.
|
| 334 |
Nitric oxide mechanism in the protective effect of antidepressants against 3-nitropropionic acid-induced cognitive deficit, glutathione and mitochondrial alterations in animal model of Huntington's disease.Behav Pharmacol. 2010 May;21(3):217-30. doi: 10.1097/fbp.0b013e32833a5bf4.
|
| 335 |
A single-subunit NADH-quinone oxidoreductase renders resistance to mammalian nerve cells against complex I inhibition.Mol Ther. 2002 Sep;6(3):336-41. doi: 10.1006/mthe.2002.0674.
|
| 336 |
Plasma neurofilament heavy chain levels in Huntington's disease.Neurosci Lett. 2007 May 7;417(3):231-3. doi: 10.1016/j.neulet.2007.02.053. Epub 2007 Feb 24.
|
| 337 |
Neurofilament light protein in blood predicts regional atrophy in Huntington disease.Neurology. 2018 Feb 20;90(8):e717-e723. doi: 10.1212/WNL.0000000000005005. Epub 2018 Jan 24.
|
| 338 |
Early down-regulation of PKC as a pro-survival mechanism in Huntington's disease.Neuromolecular Med. 2014 Mar;16(1):25-37. doi: 10.1007/s12017-013-8248-8. Epub 2013 Jul 30.
|
| 339 |
Lercanidipine boosts the efficacy of mesenchymal stem cell therapy in 3-NP-induced Huntington's disease model rats via modulation of the calcium/calcineurin/NFATc4 and Wnt/-catenin signalling pathways.Neurochem Int. 2019 Dec;131:104548. doi: 10.1016/j.neuint.2019.104548. Epub 2019 Sep 17.
|
| 340 |
Localization of neuroglobin in the brain of R6/2 mouse model of Huntington's disease.Neurol Sci. 2018 Feb;39(2):275-285. doi: 10.1007/s10072-017-3168-2. Epub 2017 Nov 3.
|
| 341 |
Increased translation as a novel pathogenic mechanism in Huntington's disease.Brain. 2019 Oct 1;142(10):3158-3175. doi: 10.1093/brain/awz230.
|
| 342 |
Decreased striatal RGS2 expression is neuroprotective in Huntington's disease (HD) and exemplifies a compensatory aspect of HD-induced gene regulation.PLoS One. 2011;6(7):e22231. doi: 10.1371/journal.pone.0022231. Epub 2011 Jul 14.
|
| 343 |
Effects of deletion of mutant huntingtin in steroidogenic factor 1 neurons on the psychiatric and metabolic phenotype in the BACHD mouse model of Huntington disease.PLoS One. 2014 Oct 1;9(10):e107691. doi: 10.1371/journal.pone.0107691. eCollection 2014.
|
| 344 |
Mapping of D4S98/S114/S113 confines the Huntington's defect to a reduced physical region at the telomere of chromosome 4.Nucleic Acids Res. 1988 Dec 23;16(24):11769-80. doi: 10.1093/nar/16.24.11769.
|
| 345 |
Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease.Sci Rep. 2018 Mar 9;8(1):4260. doi: 10.1038/s41598-018-21788-x.
|
| 346 |
Variable subcellular localization of a neuron-specific protein during NTera 2 differentiation into post-mitotic human neurons.Brain Res Mol Brain Res. 1996 Dec;42(2):202-12. doi: 10.1016/s0169-328x(96)00115-5.
|
| 347 |
Identification of NUB1 as a suppressor of mutant Huntington toxicity via enhanced protein clearance.Nat Neurosci. 2013 May;16(5):562-70. doi: 10.1038/nn.3367. Epub 2013 Mar 24.
|
| 348 |
Degeneration of ipRGCs in Mouse Models of Huntington's Disease Disrupts Non-Image-Forming Behaviors Before Motor Impairment.J Neurosci. 2019 Feb 20;39(8):1505-1524. doi: 10.1523/JNEUROSCI.0571-18.2018. Epub 2018 Dec 26.
|
| 349 |
Interaction between the Haptoglobin 2 Phenotype and Diabetes Mellitus on Systolic Pulmonary Arterial Pressure and Nitric Oxide Bioavailability in Hemodialysis Patients.J Diabetes Res. 2015;2015:613860. doi: 10.1155/2015/613860. Epub 2015 Jun 11.
|
| 350 |
Small molecule modulator of protein disulfide isomerase attenuates mutant huntingtin toxicity and inhibits endoplasmic reticulum stress in a mouse model of Huntington's disease.Hum Mol Genet. 2018 May 1;27(9):1545-1555. doi: 10.1093/hmg/ddy061.
|
| 351 |
PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains.Hum Mol Genet. 2002 Oct 1;11(21):2547-58. doi: 10.1093/hmg/11.21.2547.
|
| 352 |
Neuropathology and pathogenesis of extrapyramidal movement disorders: a critical update-I. Hypokinetic-rigid movement disorders.J Neural Transm (Vienna). 2019 Aug;126(8):933-995. doi: 10.1007/s00702-019-02028-6. Epub 2019 Jun 18.
|
| 353 |
Pregnancy-Associated Plasma Protein A2 in Hemodialysis Patients: Significance for Prognosis.Kidney Blood Press Res. 2017;42(3):509-518. doi: 10.1159/000479847. Epub 2017 Aug 30.
|
| 354 |
Ciliogenesis is regulated by a huntingtin-HAP1-PCM1 pathway and is altered in Huntington disease.J Clin Invest. 2011 Nov;121(11):4372-82. doi: 10.1172/JCI57552. Epub 2011 Oct 10.
|
| 355 |
PEP-19 immunohistochemistry defines the basal ganglia and associated structures in the adult human brain, and is dramatically reduced in Huntington's disease.Neuroscience. 1998 Oct;86(4):1055-63. doi: 10.1016/s0306-4522(98)00130-4.
|
| 356 |
PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum.Cell Death Differ. 2010 Feb;17(2):324-35. doi: 10.1038/cdd.2009.127. Epub 2009 Sep 11.
|
| 357 |
PIAS1 Regulates Mutant Huntingtin Accumulation and Huntington's Disease-Associated Phenotypes InVivo.Neuron. 2016 May 4;90(3):507-20. doi: 10.1016/j.neuron.2016.03.016. Epub 2016 Apr 14.
|
| 358 |
Inevitable isolation and the change of stress markers in hemodialysis patients during the 2015 MERS-CoV outbreak in Korea.Sci Rep. 2019 Apr 5;9(1):5676. doi: 10.1038/s41598-019-41964-x.
|
| 359 |
Adenyl cyclase activator forskolin protects against Huntington's disease-like neurodegenerative disorders.Neural Regen Res. 2017 Feb;12(2):290-300. doi: 10.4103/1673-5374.200812.
|
| 360 |
Protein C and protein S deficiencies may be related to survival among hemodialysis patients.BMC Nephrol. 2019 May 28;20(1):191. doi: 10.1186/s12882-019-1344-8.
|
| 361 |
Subjective Assessment of Sleep in Huntington Disease: Reliability of Sleep Questionnaires Compared to Polysomnography.Neurodegener Dis. 2017;17(6):330-337. doi: 10.1159/000480701. Epub 2017 Nov 24.
|
| 362 |
Gene therapy by proteasome activator, PA28, improves motor coordination and proteasome function in Huntington's disease YAC128 mice.Neuroscience. 2016 Jun 2;324:20-8. doi: 10.1016/j.neuroscience.2016.02.054. Epub 2016 Mar 2.
|
| 363 |
Prothymosin- interacts with mutant huntingtin and suppresses its cytotoxicity in cell culture.J Biol Chem. 2012 Jan 6;287(2):1279-89. doi: 10.1074/jbc.M111.294280. Epub 2011 Nov 22.
|
| 364 |
Pharmacogenetic modulation of STEP improves motor and cognitive function in a mouse model of Huntington's disease.Neurobiol Dis. 2018 Dec;120:88-97. doi: 10.1016/j.nbd.2018.08.024. Epub 2018 Aug 31.
|
| 365 |
Striatal Vulnerability in Huntington's Disease: Neuroprotection Versus Neurotoxicity.Brain Sci. 2017 Jun 7;7(6):63. doi: 10.3390/brainsci7060063.
|
| 366 |
Glucose transporter 3 is a rab11-dependent trafficking cargo and its transport to the cell surface is reduced in neurons of CAG140 Huntington's disease mice.Acta Neuropathol Commun. 2014 Dec 20;2:179. doi: 10.1186/s40478-014-0178-7.
|
| 367 |
RAN Translation in Huntington Disease.Neuron. 2015 Nov 18;88(4):667-77. doi: 10.1016/j.neuron.2015.10.038.
|
| 368 |
Bioinformatics analysis of Ras homologue enriched in the striatum, a potential target for Huntington's disease therapy.Int J Mol Med. 2019 Dec;44(6):2223-2233. doi: 10.3892/ijmm.2019.4373. Epub 2019 Oct 15.
|
| 369 |
Regulator of calcineurin (RCAN1-1L) is deficient in Huntington disease and protective against mutant huntingtin toxicity in vitro.J Biol Chem. 2009 May 1;284(18):11845-53. doi: 10.1074/jbc.M900639200. Epub 2009 Mar 6.
|
| 370 |
A Combinatorial Cell and Drug Delivery Strategy for Huntington's Disease Using Pharmacologically Active Microcarriers and RNAi Neuronally-Committed Mesenchymal Stromal Cells.Pharmaceutics. 2019 Oct 12;11(10):526. doi: 10.3390/pharmaceutics11100526.
|
| 371 |
Serelaxin treatment promotes adaptive hypertrophy but does not prevent heart failure in experimental peripartum cardiomyopathy.Cardiovasc Res. 2017 May 1;113(6):598-608. doi: 10.1093/cvr/cvw245.
|
| 372 |
Identification of differentially expressed genes and regulatory relationships in Huntington's disease by bioinformatics analysis.Mol Med Rep. 2018 Mar;17(3):4317-4326. doi: 10.3892/mmr.2018.8410. Epub 2018 Jan 9.
|
| 373 |
A genome-scale RNA-interference screen identifies RRAS signaling as a pathologic feature of Huntington's disease.PLoS Genet. 2012;8(11):e1003042. doi: 10.1371/journal.pgen.1003042. Epub 2012 Nov 29.
|
| 374 |
Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice.Hum Mol Genet. 2002 Sep 15;11(19):2233-41. doi: 10.1093/hmg/11.19.2233.
|
| 375 |
Bim contributes to the progression of Huntington's disease-associated phenotypes.Hum Mol Genet. 2020 Jan 15;29(2):216-227. doi: 10.1093/hmg/ddz275.
|
| 376 |
S-nitrosylation of dynamin-related protein 1 mediates mutant huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease.Antioxid Redox Signal. 2013 Oct 10;19(11):1173-84. doi: 10.1089/ars.2012.4928. Epub 2013 Jun 20.
|
| 377 |
Secretory carrier membrane protein 5 is an autophagy inhibitor that promotes the secretion of -synuclein via exosome.PLoS One. 2017 Jul 11;12(7):e0180892. doi: 10.1371/journal.pone.0180892. eCollection 2017.
|
| 378 |
SH3GL3 associates with the Huntingtin exon 1 protein and promotes the formation of polygln-containing protein aggregates.Mol Cell. 1998 Oct;2(4):427-36. doi: 10.1016/s1097-2765(00)80142-2.
|
| 379 |
SORLA-mediated trafficking of TrkB enhances the response of neurons to BDNF.PLoS One. 2013 Aug 19;8(8):e72164. doi: 10.1371/journal.pone.0072164. eCollection 2013.
|
| 380 |
Population-specific genetic modification of Huntington's disease in Venezuela.PLoS Genet. 2018 May 11;14(5):e1007274. doi: 10.1371/journal.pgen.1007274. eCollection 2018 May.
|
| 381 |
Relation of serum spondin-2 levels with cardiac morphology and inflammatory parameters in hemodialysis patients.Int Urol Nephrol. 2018 Nov;50(11):2091-2097. doi: 10.1007/s11255-018-1996-5. Epub 2018 Oct 1.
|
| 382 |
Spinocerebellar ataxia 2 (SCA2): morphometric analyses in 11 autopsies.Acta Neuropathol. 1999 Mar;97(3):306-10. doi: 10.1007/s004010050989.
|
| 383 |
Pathophysiology in the suprachiasmatic nucleus in mouse models of Huntington's disease.J Neurosci Res. 2018 Dec;96(12):1862-1875. doi: 10.1002/jnr.24320. Epub 2018 Aug 31.
|
| 384 |
Preimplantation genetic diagnosis of P450 oxidoreductase deficiency and Huntington Disease using three different molecular approaches simultaneously.J Assist Reprod Genet. 2009 May;26(5):263-71. doi: 10.1007/s10815-009-9327-5. Epub 2009 Jul 21.
|
| 385 |
HD phenocopies--possible role of Saitohin gene.Int J Neurosci. 2008 Mar;118(3):391-7. doi: 10.1080/00207450701593103.
|
| 386 |
On the Role of Store-Operated Calcium Entry in Acute and Chronic Neurodegenerative Diseases.Front Mol Neurosci. 2018 Mar 22;11:87. doi: 10.3389/fnmol.2018.00087. eCollection 2018.
|
| 387 |
SUMO-2 and PIAS1 modulate insoluble mutant huntingtin protein accumulation.Cell Rep. 2013 Jul 25;4(2):362-75. doi: 10.1016/j.celrep.2013.06.034. Epub 2013 Jul 18.
|
| 388 |
Effects on murine behavior and lifespan of selectively decreasing expression of mutant huntingtin allele by supt4h knockdown.PLoS Genet. 2015 Mar 11;11(3):e1005043. doi: 10.1371/journal.pgen.1005043. eCollection 2015 Mar.
|
| 389 |
Synaptic mutant huntingtin inhibits synapsin-1 phosphorylation and causes neurological symptoms.J Cell Biol. 2013 Sep 30;202(7):1123-38. doi: 10.1083/jcb.201303146.
|
| 390 |
Huntington Mice Demonstrate Diminished Pain Response in Inflammatory Pain Model.Anesth Analg. 2018 Feb;126(2):661-669. doi: 10.1213/ANE.0000000000002419.
|
| 391 |
Sp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.Science. 2002 Jun 21;296(5576):2238-43. doi: 10.1126/science.1072613. Epub 2002 May 2.
|
| 392 |
Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins.Nature. 2014 Sep 11;513(7517):256-60. doi: 10.1038/nature13466. Epub 2014 Jul 9.
|
| 393 |
Mutant huntingtin disrupts mitochondrial proteostasis by interacting with TIM23.Proc Natl Acad Sci U S A. 2019 Aug 13;116(33):16593-16602. doi: 10.1073/pnas.1904101116. Epub 2019 Jul 25.
|
| 394 |
p35 hemizygosity activates Akt but does not improve motor function in the YAC128 mouse model of Huntington's disease.Neuroscience. 2017 Jun 3;352:79-87. doi: 10.1016/j.neuroscience.2017.03.051. Epub 2017 Apr 6.
|
| 395 |
CAG Repeat Not Polyglutamine Length Determines Timing of Huntington's Disease Onset.Cell. 2019 Aug 8;178(4):887-900.e14. doi: 10.1016/j.cell.2019.06.036.
|
| 396 |
Non-pathogenic protein aggregates in skeletal muscle in MLF1 transgenic mice.J Neurol Sci. 2008 Jan 15;264(1-2):77-86. doi: 10.1016/j.jns.2007.07.027. Epub 2007 Sep 12.
|
|
|
|
|
|
|
